Updated: Nov 24, 2021
Dec 28, 2020 | By Hannah Balfour (European Pharmaceutical Review)
The Tonglian Group has developed the world’s first synthetic biological drug treatment for severe COVID-19 to receive US Food and Drug Administration (FDA) approval for Phase III trials. The drug, Carrimycin, has been demonstrated to be effective in treating patients who have been hospitalized with severe COVID-19 symptoms.
It was originally developed to treat community-acquired infections in adults caused by bacteria. Carrimycin showed strong anti-coronavirus results, inhibiting the replication of 2019-nCoV in cells, without causing significant side effects. The Phase III trials are building on testing carried out in China, the results of which have been recognized by the FDA.
Jiang Enhong, CEO of the Tonglian Group commented, “This is a major breakthrough in the treatment of COVID-19, based on international collaboration. The availability of vaccines is, of course, very important. But we know there will always be people who contract COVID, which is why it is so essential we have therapeutic treatments, particularly for anyone hospitalized with a serious case of COVID-19.”
“We hope Carrimycin will be able to help people all over the world to recover quickly from the worst symptoms of COVID-19. 2020 has been dominated by the impact of the pandemic. In 2021, we’ll be talking about using science to minimize the impact, whether that’s therapeutic treatments, vaccines or restricting infection rates.”